| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/29/2006 | WO2006066955A1 Quinoline derivative, use and production thereof, and drug containing the same |
| 06/29/2006 | WO2006066949A1 Compositions comprising an epothilone and production methods |
| 06/29/2006 | WO2006066923A2 Indole derivatives with antitumor activity |
| 06/29/2006 | WO2006066846A1 Use of thiazolidinone derivatives as antiangiogenic agents |
| 06/29/2006 | WO2006066795A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 06/29/2006 | WO2006066775A1 Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions |
| 06/29/2006 | WO2006066584A1 Novel cyanoguanidine compounds |
| 06/29/2006 | WO2006066463A1 Receptor-selective lymphotoxin deviants |
| 06/29/2006 | WO2006057886A3 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES |
| 06/29/2006 | WO2006057885A3 17,20(e)-dehydro vitamin d analogs and their uses |
| 06/29/2006 | WO2006015079A3 Erm family binding agents and their use in diagnosis and treatment of proliferative conditions |
| 06/29/2006 | US20060142580 N-phenyl-2-pyrimidine-amine derivatives |
| 06/29/2006 | US20060142577 4-Diethylamino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)-benzamide; disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease; leukemia |
| 06/29/2006 | US20060142569 Methods of synthesizing 3-amino-1,2-4-benzotriazines |
| 06/29/2006 | US20060142360 Having a central trivalent nitrogen atom to which is attached either direct or indirectly three ring systems, at least one of which is substituted by a sulfamate group and one by a halogen; steroid sulfatase and aromatase inhibitors |
| 06/29/2006 | US20060142354 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 06/29/2006 | US20060142345 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| 06/29/2006 | US20060142338 Androgen sensitive diseases; prostate cancer; skin disorders; alopecia |
| 06/29/2006 | US20060142336 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 06/29/2006 | US20060142316 synergistic mixtures of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, fluorouracil or irinocetan, for the treatment of cancers; angiogenesis inhibitors and vascular permeability reducing effect in mammals |
| 06/29/2006 | US20060142314 2-substituted-4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142313 2-substituted-4-(indazolamino)quinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142309 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
| 06/29/2006 | US20060142305 N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanine-4-ethoxycarbonylpiperazinium hydrogen sulfate; N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyguanidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide; urokinase plasminogen activator inhibitor; anticarcinogenic agent |
| 06/29/2006 | US20060142297 Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine |
| 06/29/2006 | US20060142287 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer |
| 06/29/2006 | US20060142281 Indolinone derivatives |
| 06/29/2006 | US20060142280 Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy |
| 06/29/2006 | US20060142275 Enzyme inhibitors; a 1H-imidazo[1,2-a][1,4]benzodiazepine or tetrahydroimidazo[1,2a]pyrazine derivatives; antitumor agents for treating cancer of breast, colon, pancreas, prostate, lung, ovarian, epidermal, and hematopoietics |
| 06/29/2006 | US20060142267 [6-hydroxy-2-(2-hydroxy-benzyl)-benzo [b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; [6-hydroxy-2-(2-hydroxy-benzyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; 6-(2-hydroxy-benzyl)-5-{hydroxy-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methyl}-naphthalen-2-ol |
| 06/29/2006 | US20060142266 Compounds and their uses |
| 06/29/2006 | US20060142258 Estrogen replacement therapy |
| 06/29/2006 | US20060142244 Geranyl compounds |
| 06/29/2006 | US20060142239 Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine |
| 06/29/2006 | US20060142238 Chemical compounds |
| 06/29/2006 | US20060142236 Antisense oligonucleotide modulation of raf gene expression |
| 06/29/2006 | US20060142224 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 06/29/2006 | US20060142218 Method of controlling telomere length |
| 06/29/2006 | US20060142212 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 06/29/2006 | US20060142206 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 06/29/2006 | US20060142203 Antiproliferative agents; angiogenese inhibitors; antiinflammatory agents; anticancer agents |
| 06/29/2006 | US20060141602 Packaging of positive-strand RNA virus replicon particles |
| 06/29/2006 | US20060141589 Method of producing macrolide compound |
| 06/29/2006 | US20060141580 Encoding protein with immunomodulatory activity, antiviral activity, and antitumor activity; treating any Type 1 interferon treatable disease including cancer; determining if a patient will respond to interferon treatment; transgenic animals |
| 06/29/2006 | US20060141579 Cytokine zcytor17 ligand polynucleotides |
| 06/29/2006 | US20060141545 Cancer treatment kits using antibodies to aminophospholipids |
| 06/29/2006 | US20060141455 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 06/29/2006 | US20060141454 detection of mesenchymal tumoral cells by using the Slug (zinc fingers domains) gene; biomarker |
| 06/29/2006 | US20060141453 Prokineticin polypeptides, related compositions and methods |
| 06/29/2006 | US20060141080 Extracting crushed plant material Cuminum cyminum with water or 50% aqueous alcoholic solvent; extracting a portion of the aqueous extract with n-butanol, separating -butanol layer and an aqueous layer, evaporating, and freeze drying the aqueous layer |
| 06/29/2006 | US20060141042 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 06/29/2006 | US20060141022 Soft capsule preparation |
| 06/29/2006 | US20060141019 Liposome |
| 06/29/2006 | US20060140967 Immunotherapy; detecting CD8 expressing T cells; biodrugs generate an immune response to breast cancer and prostate cancer cells that express TARP (T cell receptor gamma Alternate Reading Frame Protein); vaccines |
| 06/29/2006 | US20060140965 Immunogenic compositions comprising a xenogenic prostate protein p501s |
| 06/29/2006 | US20060140962 Combination treatment of pancreatic cancer |
| 06/29/2006 | US20060140961 Compositions and methods for the diagnosis and treatment of tumor |
| 06/29/2006 | US20060140954 Novel human protein kinases and protein kinase-like enzymes |
| 06/29/2006 | US20060140937 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 06/29/2006 | US20060140922 Modified by introduction of nucleic acid molecule comprising a nucleic acid sequence encoding granulocyte macrophage-colony stimulating factor (GM-CSF) operably linked to a promoter; contains cancer antigen; immunotherapy |
| 06/29/2006 | US20060140920 Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain |
| 06/29/2006 | US20060140907 Central airway administration for systemic delivery of therapeutics |
| 06/29/2006 | US20060140858 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 06/29/2006 | DE102004061503A1 New meta-substituted thiazolidinone compounds are polo-like kinase inhibitors useful to treat cancers, autoimmune-, cardiovascular-, infectious-, nephrological-, nephrological- and neurodegenerative-diseases |
| 06/29/2006 | DE102004061288A1 New 3-amino-pyrazolo(3,4b)pyridine derivatives are protein tyrosine kinases inhibitors useful e.g. for treating hyperproliferation of body cells, neurodegenerative disease, blood vessel disease and angiogenic disease |
| 06/29/2006 | CA2820728A1 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 06/29/2006 | CA2799802A1 Antibodies directed to angiopoietin-2 and uses thereof |
| 06/29/2006 | CA2592249A1 Binding proteins specific for human matriptase |
| 06/29/2006 | CA2592162A1 Therapeutic compounds isolated form calomeria amarnthoides |
| 06/29/2006 | CA2592009A1 Quinoline derivative, its use, production and pharmaceutical agents containing the latter |
| 06/29/2006 | CA2592004A1 Use of thiazolidinone derivatives as antiangiogenic agents |
| 06/29/2006 | CA2592002A1 Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions |
| 06/29/2006 | CA2591997A1 Compositions comprising an epothilone and production methods |
| 06/29/2006 | CA2591980A1 Indole derivatives with antitumor activity |
| 06/29/2006 | CA2591705A1 Novel farnesyl protein transferase inhibitors as antitumor agents |
| 06/29/2006 | CA2591304A1 Compositions and methods relating to anti-igf-1 receptor antibodies |
| 06/29/2006 | CA2591215A1 Cdc25 phosphatase inhibitors |
| 06/29/2006 | CA2591208A1 Pyrazines and pyridines and derivatives thereof as therapeutic compounds |
| 06/29/2006 | CA2590742A1 Sulfonamido-macrocycles as tie2 inhibitors |
| 06/29/2006 | CA2590522A1 Sulfonamido-macrocycles as tie2 inhibitors |
| 06/29/2006 | CA2589877A1 Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| 06/29/2006 | CA2589779A1 Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| 06/29/2006 | CA2589773A1 Pyridine carboxamide derivatives for use as anticancer agents |
| 06/29/2006 | CA2589748A1 Heterocyclic compounds as ccr2b antagonists |
| 06/29/2006 | CA2588921A1 Pyrrolidine inhibitors of iap |
| 06/29/2006 | CA2588220A1 Heteroaromatic derivatives useful as anticancer agents |
| 06/29/2006 | CA2587088A1 Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents |
| 06/28/2006 | EP1674575A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 06/28/2006 | EP1674564A1 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor |
| 06/28/2006 | EP1674470A1 Sulfonamido-macrocycles as Tie2 inhibitors |
| 06/28/2006 | EP1674469A1 Sulfonamido-macrocycles as Tie2 inhibitors |
| 06/28/2006 | EP1674467A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 06/28/2006 | EP1674466A1 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| 06/28/2006 | EP1674457A1 Derivatives of squaric acid with anti-proliferative activity |
| 06/28/2006 | EP1674456A2 Substituted alpha-halo-beta-keto-pyridinylpropanoates |
| 06/28/2006 | EP1674452A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 06/28/2006 | EP1674111A1 Anti-glypican 3 antibody |
| 06/28/2006 | EP1674101A1 Cinnamates of Benzo[b]pyrano[3,2-h]acridin-7-one, process for preparation thereof and their pharmaceutical composition |
| 06/28/2006 | EP1674100A1 Angiogenesis inhibitor |
| 06/28/2006 | EP1674098A1 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |